TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study

被引：0
|
作者：
Angevin, E.
Lopez, J. A.
Pande, A.
Moldovan, C.
Shi, M.
Soria, J. C.
Wang, X.
Harzstark, A.
Saro, J.
Escudier, B.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Novartis Oncol, E Hanover, NJ USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3563
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCC)
    Cen, P.
    Daleiden, A.
    Doshi, G.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Patel, P. H.
    Kondagunta, G. V.
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] PHASE II MULTICENTRIC STUDY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (MRCC) WITH A POOR PROGNOSIS REFRACTORY TO IMMUNOTHERAPY
    Longo, N.
    Di Lorenzo, G.
    Fusco, F.
    Verze, P.
    Barba, C.
    Arcaniolo, D.
    Mirone, V
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 183 - 183
  • [24] Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).
    Esteban, Emilio
    del Muro, Xavier Garcia
    Sepulveda, Juan Manuel
    Maroto, Pablo
    Diaz, Enrique Gallardo
    del Alba, Aranzazu Gonzalez
    Etxaniz, Olatz
    Guix, Marta
    Gonzalez-Larriba, Jose-Luis
    Arija, Jose Angel Arranz
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation
    Scheid, Christof
    Reece, Donna
    Beksac, Meral
    Spencer, Andrew
    Callander, Natalie
    Sonneveld, Pieter
    Kalimi, Ghulam
    Cai, Can
    Shi, Michael
    Scott, Jeffrey W.
    Stewart, A. Keith
    BLOOD, 2012, 120 (21)
  • [26] Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment
    Mancuso, A. P.
    De Paola, E. Donato
    Catalano, A.
    Calabro, F.
    Messina, C.
    Zivi, A.
    Cerbone, L.
    Vigna, L.
    Caristo, R.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).
    De Mulder, P. H.
    Roigas, J.
    Gillessen, S.
    Srinivas, S.
    Pisa, P.
    Vogelzang, N.
    Fountzilas, G.
    Peschel, C.
    Baum, C.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 223S - 223S
  • [28] A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC)
    Mahoney, Kathleen Margaret
    Cheng, SuChun
    Bhatt, Rupal Satish
    Simpson, Mekailah Inter
    Atkins, Michael B.
    Puzanov, Igor
    Signoretti, Sabina
    Michaelson, M. Dror
    McDermott, David F.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Phase I study of IMP321 in metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Brignone, Chrystelle
    Grygar, Caroline
    Marcu, Manon
    Triebel, Frederic
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 885 - 885
  • [30] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
12345